Barclays Maintains Overweight on Bruker, Raises Price Target to $70

Barclays analyst Luke Sergott has maintained an Overweight rating on Bruker (NASDAQ: BRKR) and increased the price target from $58 to $70. This adjustment reflects a positive outlook on the company's performance.